RBC Capital analyst Gregory Renza maintains $Perspective Therapeutics (CATX.US)$ with a buy rating, and adjusts the target price from $25 to $16.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 14.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Perspective Therapeutics (CATX.US)$'s main analysts recently are as follows:
Perspective Therapeutics reported outcomes for VMT-alpha-NET that fell short of expected response rates compared to competitors. Despite potential opportunities to enhance outcomes at elevated doses, further data might not be accessible until late-2025, subject to FDA approvals for advancing trials. Additionally, earliest findings for VMT01 in melanoma revealed complications due to kidney accumulation, which restrict dose increments. These factors are likely to impact the stock until new data from combination studies for VMT01 becomes available.
Initial results from the early phase study of VMT-a-NET conveyed promising indications, yet underscored the necessity for patience in optimizing dosages. There is perceived potential for commercial success with Perspective Therapeutics' primary specific chelator spanning its entire pipeline and platform.
Yesterday's sell-off in Perspective Therapeutics was regarded as an overreaction to the preliminary data from the dose escalation phase of the VMT-alpha-NET program, according to analysts. The findings indicated clinical activity correlating with dose intensity alongside a positive safety profile, thus endorsing the continuation of the dose escalation process. Analysts suggest seizing the opportunity to buy during this period of weakness as the company's stock valuation approaches its cash levels.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
加皇资本市场分析师Gregory Renza维持$Perspective Therapeutics (CATX.US)$买入评级，并将目标价从25美元下调至16美元。
根据TipRanks数据显示，该分析师近一年总胜率为46.3%，总平均回报率为14.3%。
此外，综合报道，$Perspective Therapeutics (CATX.US)$近期主要分析师观点如下：
透视治疗报告了VMt-alpha-NEt的结果，与竞争对手相比，预期的反应率未达到预期。尽管存在提高剂量以增强结果的潜在机会，但在获得FDA批准推进试验之前，直至2025年底之前可能无法获得进一步数据。此外，有关VMT01在黑色素瘤中的最早发现显示肾脏积累导致了并发症，这限制了剂量增加。这些因素可能会影响该股票，直到VMT01的联合研究的新数据变得可用。
VMt-a-NEt早期研究的初步结果传达了有希望的迹象，但也强调了在优化剂量方面需要耐心。透视治疗公司在其整个管道和平台上使用主要特定螯合剂具有潜在的商业成功可能性。
根据分析师的说法，昨天在透视治疗公司的抛售被视为对VMt-alpha-NEt项目剂量递增阶段的初步数据的过度反应。研究结果表明，与剂量强度相关的临床活性，以及积极的安全性概况，从而支持继续剂量递增过程。分析师建议在这个弱势期间抓住买入机会，因为公司股价接近其现金水平。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
